Verrica Pharmaceuticals Inc. VRCA PHARMA
Company Overview
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 57.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $35.58M (+370.2% YoY); net profit $-17.89M.
- Trailing 12 Months Year-on-year growth — revenue -53.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 57.9%, profit CAGR 9.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 57.93% |
| 1 Year: | -53.90% |
Compounded Profit Growth
| 5 Years: | 8.99% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -20.18% |
| 6 Months: | -7.39% |
| 3 Months: | -12.19% |
| 1 Month: | +3.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.44 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 57.9% over 5 years.
CONS
- Trading 42.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VRCA Verrica Pharmaceuticals Inc. PHARMA | 5.26 | -3.11 | $90.36M | 0.00% | -38.90% | -72.29% | 57.93% | 8.99% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00M | 0 | 0 | 431.00K | 214.00K | 8.32M | 37.00K | 182.00K | 2.92M | 3.83M | 5.18M | -1.78M | - | 3.44M | 12.70M | 14.34M | 5.09M | 5.02M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 437.00K | 494.00K | 1.11M | 1.40M | 889.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00M | 12.21M | 13.23M | 3.69M | 4.13M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.13M | 10.70M | 11.61M | 10.64M | 13.85M |
| Operating Income | -570.00K | -1.09M | -1.36M | -1.43M | -1.89M | -5.47M | -6.33M | -8.19M | -8.03M | -7.52M | -6.54M | -7.99M | -9.88M | -8.63M | -9.64M | 60.00K | -10.73M | -11.77M | -7.41M | -9.12M | 1.45M | -7.09M | -11.62M | -23.92M | -18.60M | -15.21M | -20.70M | - | -8.13M | 1.51M | 1.63M | -6.95M | -9.71M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.33M | 2.53M | 2.00M | -6.57M | -9.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.20M | 2.13M | 2.09M | 1.31M | 160.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.74M | 204.00K | -274.00K | -8.07M | -9.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -570.00K | -1.09M | -1.36M | -1.44M | -1.85M | -5.32M | -5.91M | -7.58M | -7.48M | -7.00M | -6.09M | -7.64M | -9.82M | -9.41M | -10.49M | -936.00K | -11.78M | -12.83M | -8.47M | -10.17M | 83.00K | -6.59M | -10.99M | -24.80M | -20.33M | -17.19M | -22.86M | - | -9.74M | 204.00K | -274.00K | -8.07M | -9.68M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.43 | -0.47 | -0.31 | -0.37 | 0.00 | -0.15 | -0.24 | -0.54 | -0.44 | -3.70 | -4.88 | - | -1.00 | 0.02 | -0.03 | -0.57 | -0.45 |
| R&D Expense | 515.00K | 977.00K | 1.12M | 1.12M | 927.00K | 3.52M | 3.47M | 4.92M | 4.49M | 3.93M | 3.05M | 3.97M | 4.89M | 3.52M | 4.99M | 5.36M | 3.45M | 3.76M | 2.44M | 3.94M | 2.78M | 2.74M | 5.72M | 6.51M | 4.95M | 3.32M | 2.40M | - | 2.28M | 1.85M | 2.21M | - | 3.86M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 9.03M | 5.12M | 7.57M | 35.58M |
| Cost of Revenue | - | - | - | - | - | 725.00K | 746.00K | 2.74M | 3.44M |
| Gross Profit | - | - | - | - | - | 8.31M | 4.38M | 4.83M | 32.14M |
| Operating Expenses | - | - | - | - | - | 29.60M | 67.60M | 70.66M | 44.08M |
| Operating Income | -4.46M | -21.88M | -30.08M | -40.18M | - | -21.30M | -63.22M | -65.84M | -11.94M |
| EBITDA | - | - | - | - | - | -21.60M | -62.20M | -65.90M | -9.36M |
| Interest Expense | - | - | - | - | - | 2.17M | 3.96M | 9.41M | 7.74M |
| Pretax Income | - | - | - | - | - | -24.49M | -67.00M | -76.58M | -17.89M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -4.46M | -20.65M | -28.21M | -42.69M | - | -24.49M | -67.00M | -76.58M | -17.89M |
| Diluted EPS | - | - | - | - | - | -7.20 | -14.80 | -14.80 | -1.68 |
| R&D Expense | 3.73M | 12.83M | 15.44M | 15.67M | 15.93M | 12.20M | 20.30M | 11.84M | 8.86M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Jul 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.08M | 91.91M | 68.42M | 74.15M | - | - | 44.72M | 81.60M | 54.13M | 47.13M |
| Current Assets | - | - | - | - | - | - | - | 39.12M | 77.53M | 51.18M | 42.54M |
| Cash & Equivalents | 527.00K | 8.66M | 10.27M | 9.24M | 10.69M | - | 40.00M | 34.27M | 69.55M | 46.33M | 30.15M |
| Inventory | - | - | - | - | - | - | - | 0 | 1.02M | 2.46M | 2.24M |
| Receivables | - | - | - | - | - | - | - | 388.00K | 4.25M | 48.00K | 5.26M |
| Total Liabilities | - | 616.00K | 2.48M | 3.41M | 41.17M | - | - | 4.69M | 61.83M | 63.99M | 22.39M |
| Current Liabilities | - | 616.00K | 2.48M | 3.35M | 39.48M | - | - | 3.46M | 17.02M | 29.01M | 16.44M |
| Long Term Debt | - | - | - | - | - | - | - | - | 42.87M | 30.98M | - |
| Total Debt | - | - | - | - | - | - | - | 1.53M | 45.51M | 45.94M | 1.63M |
| Total Equity | -2.66M | -7.04M | 89.43M | 65.02M | 32.99M | - | - | 40.03M | 19.76M | -9.86M | 24.74M |
| Shares Outstanding | - | - | - | - | - | - | - | 4.12M | 4.25M | 9.19M | 17.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.58M | -17.87M | -27.41M | -30.21M | - | -18.65M | -38.58M | -60.93M | -17.63M |
| Investing Cash Flow | - | -79.89M | 25.95M | -3.58M | - | 54.04M | -362.00K | -19.00K | 0 |
| Financing Cash Flow | 12.72M | 99.38M | 423.00K | 35.23M | - | -16.87M | 74.21M | 37.73M | 1.45M |
| Capital Expenditure | - | -774.00K | -682.00K | -1.47M | -883.00K | -302.00K | -362.00K | -27.00K | - |
| Free Cash Flow | - | -18.65M | -28.09M | -31.68M | - | -18.95M | -38.94M | -60.95M | -17.63M |
| Net Change in Cash | - | - | - | - | - | 18.52M | 35.27M | -23.22M | -16.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 92.0% | 85.4% | 63.8% | 90.3% |
| Operating Margin % | - | - | - | - | - | -235.8% | -1,233.8% | -870.2% | -33.6% |
| Net Margin % | - | - | - | - | - | -271.1% | -1,307.5% | -1,012.1% | -50.3% |
| ROE % | 63.3% | -23.1% | -43.4% | -129.4% | - | -61.2% | -339.0% | 776.7% | -72.3% |
| ROCE % | -52.6% | -24.5% | -46.2% | -115.9% | - | -51.6% | -97.9% | -262.1% | -38.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Caligan Partners, LP | 5.38% | 923.91K | $4.11M |
| 2 | Cannell Capital LLC | 4.56% | 783.92K | $3.49M |
| 3 | Affinity Asset Advisors, Llc | 4.12% | 707.34K | $3.15M |
| 4 | Velan Capital Investment Management LP | 2.75% | 471.56K | $2.10M |
| 5 | Armistice Capital, LLC | 2.48% | 426.30K | $1.90M |
| 6 | Vanguard Capital Management LLC | 1.63% | 279.31K | $1.24M |
| 7 | Boothbay Fund Management, LLC | 1.63% | 280.73K | $1.25M |
| 8 | Mariner, LLC | 1.21% | 207.23K | $922.17K |
| 9 | Geode Capital Management, LLC | 0.80% | 138.16K | $614.81K |
| 10 | Blackrock Inc. | 0.43% | 74.34K | $330.83K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRCA
A contagious skin infection affects about 6 million, mostly children. Verrica presents Sept. 14. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQMVg4RmJUeEwybHRvdG5ULWFkNG43RWRqU29tRDYzQllXV1lkN1NXXzc1R2RjMDNKZ2duZDgyM3dnV2F5aEpMaE94S1FCSjNBY3V2NUp0WnpOMHpWYmVUdm92R2FaZXc4MVFZUHhGeHJpYVk1bHJWOUJzNGlmZkVCbDBEWS15U3ZTQWxFcX…
Verrica Pharmaceuticals Stock Price Forecast. Should You Buy VRCA? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE02WlpkQl8zS0ZDMVBscmlUQzUwRlNMYTRTNEdHUnlTaklEN2s3V1pfaEZndzhlVngyajBBODl4SXBDUE9TWjV4Zg?oc=5" target="_blank">Verrica Pharmaceuticals Stock Price Forecast. Should You Buy VRCA?</a…
Discipline and Rules-Based Execution in VRCA Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQM3g2Ui0wcHpiVEczc0tEeXBSMTFjZGV1Nk9MWVRWUmNDN1VlNWo3UGhLZm5Sa2V6MXVzUVJPajduUEZXUG10LU1jcXZrZ1dBTktDVmQ1dkRrQkRWdnp5dUZqSER2Z003TWZ2MVVCWExFTWJRODhHSEl2QzBqUGg4YVVKdEJ3TlVsd2gzVF…
$VRCA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOXzM5alFfT0hqUnBYaHNBTGFTLWpQUW5yVFE5MWpuRERNdHRCWGFnR1NiX01uM2JNa2VMV3hxNllLQ2V4TDNtLTMyTVJabHlXMm9LMFdsUF9jNTRFNGpXcjZPRGd6anE4YWE1SV9janpsZnR1Zmd6SHFPeEV1UkpqT3FKcHA1S0pZMXhld3…
VRCA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE4zUEJHUXZUVmVxSnYyMXBGaWZvRUNucUhEN3RqT2JSR0hCQjVEZm9HZWV0LVc1M2JSWDNqZ3Z5YUZPZnMtQURCaTJrUEhnYU9UQmp1OUQ0OTRyMG0tQWNZMG4zNW9jdTZ1elRtZUVWZDdYdms3QjNyeWdn?oc=5" target="_blank">VRC…
VRCA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE01QjVITkhLQXZOOUtzWFpYbFBNaTZhTHg0alREV0xBNzRvNkxLSU5fSUlBSTNpUGdYeVJrU2VvX2dQczl0TlE?oc=5" target="_blank">VRCA</a> <font color="#6f6f6f">Finviz</font>…
VRCA — Frequently Asked Questions
What is the current share price of Verrica Pharmaceuticals Inc. (VRCA)?
As of 2026-09-19 21:16 PDT, Verrica Pharmaceuticals Inc. (VRCA) trades at $5.26 on NasdaqCM. Its 52-week range is $3.28 to $9.10.
What is the market capitalisation of VRCA?
Verrica Pharmaceuticals Inc. (VRCA) has a market capitalisation of $90.36M on NasdaqCM.
What is the P/E ratio of VRCA?
VRCA trades at a trailing price-to-earnings (P/E) ratio of -3.11. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 17.73.
What is the return on equity (ROE) of VRCA?
VRCA has a return on equity (ROE) of -72.29%. Its return on capital employed (ROCE) is -38.90%.
Is VRCA a good stock to buy?
This page provides a data-driven analysis of Verrica Pharmaceuticals Inc. (VRCA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.